塩野義製薬ShionogiAnnouncesRevisionstotheSecondMedium-TermBusinessPlan
MSTGは、未来の資産家たちの投資能力を向上させる事を目的とした株式仮想取引ゲームです。
テーマ |  上場企業 |  ニュース |  地域 |  問い合わせ |

 ログイン
ユーザ名:

パスワード:


パスワード紛失
新規登録

 マーケットサマリー
NK22522,201+110.4
TOPIX1,617+2.0
DOW26,560+110.0
NASDAQ7,998+2.0
$/¥111.9+0.08

 MSTGお奨め銘柄
[8341]七十七銀行
[8367]南都銀行
[8524]北洋銀行
[8508]Jトラスト
[7189]西日本フィナ
[8336]武蔵野銀行

 バーゲン銘柄
[3529]アツギ
[7999]MUTOHホ
[7703]川澄化学工業
[7925]前澤化成工業
[5909]コロナ

 MSTG NEWS

Check
 上場企業ニュース
塩野義製薬ShionogiAnnouncesRevisionstotheSecondMedium-TermBusinessPlan

April4,2007Shionogi&Co.,Ltd.ShionogiAnnouncesRevisionstotheSecondMedium-TermBusinessPlanOsaka,April4,2007–Basedonareviewofthefirsttwoyearsofthesecondmedium-termbusinessplan(coveringtheperiodfromfiscal2005tofiscal2009),Shionogi&Co.,Ltd.(HeadOffice:Osaka;President:MotozoShiono)announcesthefollowingrevisionstothegoalsandtargetsforthecomingthreeyears.StatusoftheSecondMedium-TermBusinessPlanUnderthefirstmedium-termbusinessplan,Shionogiestablishedanoperatingstructurewithafocusonprescriptiondrugsasitsbase.Thesecondmedium-termbusinessplanwaspositionedasaperiodforaggressivelypreparingforlong-termgrowthasapharmaceuticalcompanyunderthebannerof“preparingforasignificantleapforward.”Inparticular,Shionogihasworkedtoconcentrateresearch,development,salesandmarketingresourcesinkeyareas,withtheaimofestablishingasecondandthirdtargetareainadditiontoShionogi’scoreantibioticsbusiness.Atthesametime,Shionogihasaimedtosteadilybuildabaseforfull-scaleoverseasdevelopment.Inresearchanddevelopment,Shionogiisconcentratingresourcesinthethreetargetareasofinfections,painandmetabolicsyndrome,withtheaimofadvancingatleastfivenewchemicalcompoundstoPhaseIIormoreadvancedstagesbytheendoffiscal2009.Atpresent,threecompoundshaveadvancedtothedevelopmentstage:S-2367,S-364735andS-777469.Developmentofthesethreecompoundsiscurrentlyunderway,withaneyeonfutureoverseasbusinessdevelopment.Shionogihassteadilylaunchedorappliedformanufacturingapprovalfordrugsthatareinthefinalstageofthedevelopmentpipeline.Inaddition,aggressiveeffortstoestablishacontinuouspipelinestreamresultedinthein-licensingofAdapalene(acne)andPeramivir(influenza).InitiativesaimedatachievingtheCompany’sresearchanddevelopmentgoalsarethuslargelyproceedingasplanned.Insalesandmarketing,Shionogiisworkingtofurtherexpanditspresenceintheareaofantibiotics,andlaunchedFinibax®andAvelox®infiscal2005.Intheareaof


cancer-relatedpain,Shionogiisconductingpromotionalactivitiesfocusedonimprovingqualityoflifethroughalleviationofcancerpainandpromotingeducationalactivitiesregardingthemedicaluseofnarcotics.Intheareaofmetabolicsyndrome,ShionogishiftedtoregularsalesofCrestor®inSeptember2006aftercompletingpost-marketingsurveillancewithascaleof10,000subjectswithAstraZenecasixmonthsaheadofschedule.ThishasallowedtheCompanytogetanearlystartonfull-scaleprogramstoprovideinformationonCrestor®,whichwillbeacrucialcoreproduct.Throughtheseefforts,Shionogihasstrengthenedtrainingofmedicalrepresentatives(MRs)andimprovedtheircapabilitiessotheyareconstantlyawareofmedicalneeds.However,Shionogimuststillimproveitssalesandmarketingorganization,suchasbyenhancingcoordinationbetweenmarketingfunctionsandsalesdivisions.Inaddition,conditionsintheprescriptiondrugmarketarebecomingmorechallengingthanexpected.Consequently,domesticsalesofprescriptiondrugshavenotreachedtarget.Moreover,higherresearchanddevelopmentexpenseshaveoffsetanincreaseinroyaltyrevenues,whichhaskeptShionogifromachievingitsincometargets.RevisedTargetsShionogihasreviseditstargetsforfiscal2007andfiscal2009,thefinalyearofthesecondmedium-termbusinessplan,aftertakingintoaccountfactorsincludingtheCompany’sperformanceoverthelasttwoyearsandchangesinitsoperatingenvironment.Therevisedtargetsareasfollows.(Millionyen)
FY2007(YearendedMarch2008)OriginaltargetNetsalesOperatingincomeNetincomeR&Dexpenses35,00044,00024,00041,000(11,000)(3,000)59,00050,00048,00050,000(11,000)0246,00053,200Revisedtarget215,00040,000Increase(decrease)(31,000)(13,200)FY2009(YearendedMarch2010)Originaltarget305,00098,000Revisedtarget270,00080,000Increase(decrease)(35,000)(18,000)


 情報提供元:http://www.newtech.co.jp/ir/pdf/070404.pdf
 ビジネス関連商品

 PR
利用者が当該情報などに基づいて被ったとされるいかなる損害についても当サイトは責任を負いません。

Copyright (C) 2010 MSTGV.COM. All Rights Reserved.